Tevogen Teams Up with Microsoft to Supercharge AI-Driven Drug Development

Tevogen Bio has partnered with Microsoft for Startups to enhance its Tevogen AI initiative, aiming to accelerate and reduce costs in developing therapies for infectious diseases and cancers. Leveraging Microsoft’s advanced AI, Tevogen plans to refine its proprietary algorithms and streamline drug discovery. CIO Mittul Mehta, a former Microsoft employee, is optimistic about the collaboration’s potential to make personalized therapeutics more accessible. With positive clinical trials and strong IP, this partnership could transform the biotech landscape.